Results 11 to 20 of about 23,676 (191)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

Frontiers in Oncology, 2023
RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently ...
Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William, William Nassib William   +6 more
doaj   +1 more source

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

JTO Clinical and Research Reports, 2020
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogenic ...
Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD   +1 more
doaj   +1 more source

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Frontiers in Oncology, 2021
Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a
Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Gouji Toyokawa, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Kenichi Taguchi, Tatsuro Okamoto, Takashi Seto   +10 more
doaj   +1 more source

Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors

Molecules, 2021
RET (rearranged during transfection) kinase, one of the receptor tyrosine kinases, plays a crucial role in the development of the human nervous system.
Swapnil P. Bhujbal, Seketoulie Keretsu, Seung Joo Cho   +2 more
doaj   +1 more source

Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability

Journal of Advanced Research, 2023
Introduction: The structural and dynamic determinants that confer highly selective RET kinase inhibition are poorly understood. Objectives: To explore the druggability landscape of the RET active site in order to uncover structural and dynamic ...
Moustafa A. Shehata, Julia Contreras, Ana Martín-Hurtado, Aurane Froux, Hossam Taha Mohamed, Ahmed A. El-Sherif, Iván Plaza-Menacho   +6 more
doaj   +1 more source

Precious Gene: The Application of RET-Altered Inhibitors

Molecules, 2022
The well-known proto-oncogene rearrangement during transfection (RET), also known as ret proto-oncogene Homo sapiens (human), is a rare gene that is involved in the physiological development of some organ systems and can activate various cancers, such as
Qitao Gou, Xiaochuan Gan, Longhao Li, Qiheng Gou, Tao Zhang   +4 more
doaj   +1 more source

RET signaling in breast cancer therapeutic resistance and metastasis

Breast Cancer Research, 2023
RET, a single-pass receptor tyrosine kinase encoded on human chromosome 10, is well known to the field of developmental biology for its role in the ontogenesis of the central and enteric nervous systems and the kidney.
Geoffrey Pecar, Simeng Liu, Jagmohan Hooda, Jennifer M. Atkinson, Steffi Oesterreich, Adrian V. Lee   +5 more
doaj   +1 more source

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance

European Thyroid Journal, 2023
Medullary thyroid carcinoma (MTC) is a rare but aggressive thyroid tumor, with 25% of hereditary and 75% of sporadic forms. RET mutations are found in 98% of hereditary MTC and in 55% of sporadic MTC (1).
Ségolène Hescot, Julien Masliah-Planchon, Pauline du Rusquec, Célia Dupain, Maud Kamal, Vincent Servois, Ivan Bieche   +6 more
doaj   +1 more source

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Disease Models & Mechanisms, 2021
Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms.
Takuo Hayashi, Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic, Shinji Kohsaka, Ken Suzawa, Zebing Liu, Siddharth Kunte, Marissa S. Mattar, Inna Khodos, Monika A. Davare, Alexander Drilon, Emily Cheng, Elisa de Stanchina, Marc Ladanyi, Romel Somwar   +21 more
doaj   +1 more source

Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade [version 2; referees: 4 approved]

F1000Research, 2016
RET (REarranged during Transfection) is a receptor tyrosine kinase, which plays pivotal roles in regulating cell survival, differentiation, proliferation, migration and chemotaxis.
Amanda J. Watson, Gemma V. Hopkins, Samantha Hitchin, Habiba Begum, Stuart Jones, Allan Jordan, Sarah Holt, H. Nikki March, Rebecca Newton, Helen Small, Alex Stowell, Ian D. Waddell, Bohdan Waszkowycz, Donald J. Ogilvie   +13 more
doaj   +1 more source